Validation of Rapid Antibody (IgM – IgG) Test Kit for SARS-CoV-2 Infection in Surabaya, Indonesia
Article Sidebar
Main Article Content
Abstract
At the beginning of the Corona Virus Disease 2019 (COVID-19) pandemic, rapid test examinations were widely used as a screening for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. The purpose of this examination was to detect SARS-CoV-2 IgM/IgG antibodies in the patient's body. One of these tests uses the immunochromatographic method. This study aims to determine the validity of immunochromatography. The study was conducted from August to September 2020. The sample used in this study was 100 patients. The research was conducted at Husada Utama Hospital Surabaya, Indonesia. According to the study's findings, the Zybio brand reagent kit has an accuracy of 85%, a sensitivity of 82%, a specificity of 88%, a positive predictive value of 87%, and a negative predictive value of 83%. In the group of patients who experienced clinical symptoms, < 7 had a sensitivity of 50%, specificity of 88%, positive predictive value of 60%, negative predictive value of 83%, and accuracy of 77.94% while the group of patients experiencing clinical symptoms > 7 days, had a sensitivity value of 100 %, specificity of 88%, positive predictive value of 84%, negative predictive value of 100%, and accuracy of 92.68%. Based on these results, the conclusion is that the Zybio brand reagent kit has a relatively high sensitivity, specificity, positive predictive value, negative value, and sample accuracy. In the group with clinical sensitivity < 7 days, the positive predictive value and accuracy are lower than the sample group with clinical symptoms > 7 days but have the same specificity.
Downloads
Article Details
Copyright (c) 2022 Museyaroh Museyaroh, Puspa Wardani, Aryati Aryati, Evy Diah Woelansari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Adhikari SP, Meng S, Wu Y, Mao Y, Ye R, Wang Q, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of COVID during the early outbreak period. Infect Dis Poverty. 2020;9(29):1–12. https://doi.org/10.1186/s40249-020-00646-x DOI: https://doi.org/10.1186/s40249-020-00646-x
Yuki K, Fujiogi M, Koutsogiannaki S. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. COVID-19 pathophysiology: A review. 2020;(January). https://doi.org/10.1016/j.clim.2020.108427 DOI: https://doi.org/10.1016/j.clim.2020.108427
World Health Organization. Rational use of personal protective equipment for coronavirus disease (COVID-19). Geneva: World Health Organization 2020 ;202 download at https://www.who.int/publications/i/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages
Han Y. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID ‐ 19): A Chinese perspective. 2020;(February):1–6.DOI: 10.1002/jmv.25749
Özdemir Ö. Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. 2020;42(3):242–7. https://doi.org/10.14744/etd.2020.99836 DOI: https://doi.org/10.14744/etd.2020.99836
Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. 2020J Med Virol. https://doi.org/10.1002/jmv.25749 DOI: https://doi.org/10.1002/jmv.25749
World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Geneva: World Health Organization; 2020 :78
Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM ‐ IgG combined antibody test for SARS ‐ CoV ‐ 2 infection diagnosis. J Med Virol [Internet]. 2020: 23 -45. https://doi/10.1002/jmv.25727 DOI: https://doi.org/10.1002/jmv.25727
Hidayati D. the Profile of Population that confirmed positive for Covid-19 and died: Indonesia and DKI Jakarta Cases. J Kependud Indones. 2020: 2902: https://doi.org/10.14203/jki.v0i0.541 DOI: https://doi.org/10.14203/jki.v0i0.541
PDS. Revisi Panduan Tatalaksana Pemeriksaan Antibodi SARS- CoV-2 (PDS PatKLIn) Pemeriksaan Antibodi Sars-Cov-2. 2022;(5).
Spicuzza L, Montineri A, Manuele R, Crimi C, Pistorio MP, Campisi R, et al. Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report. J Infect [Internet]. 2020;81(2): e53–4. Available from: https://doi.org/10.1016/j.jinf.2020.04.022 DOI: https://doi.org/10.1016/j.jinf.2020.04.022
Liu Ying, Liu Yue-ping, a Diao Bo2 Ren Feifei, Wang Yue, Ding Jinya at., al.. Diagnostic Indexes of a Rapid IgG/IgM Combined antibody test for SARS-CoV-2. 2020: Original Article. medRxiv. https://doi.org/10.1128/JCM.01224-20 DOI: https://doi.org/10.1101/2020.03.26.20044883
Barbosa VA de F, Gomes JC, de Santana MA, de Lima CL, Calado RB, Bertoldo Junior CR, et al. Covid-19 rapid test by combining a random forest-based web system and blood tests. 2020: department of Mechanical Engineering, Federal University of Pernambuco, Recife, Brazil. https://doi.org/10.1080/07391102.2021.1966509 DOI: https://doi.org/10.1080/07391102.2021.1966509
Andrey DO, Cohen P, Meyer B, Torriani G, Yerly S, Mazza L, et al. Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. Eur J Clin Invest. 2020;50(10):1–7. https://doi.org/10.1111/j.1469-0691.2004.01009.x DOI: https://doi.org/10.1111/eci.13357
Hoffman T, Nissen K, Krambrich J, Rönnberg B, Esmaeilzadeh M, Salaneck E, et al. Evaluation of a COVID-19 IgM and IgG rapid test: an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol [Internet]. 2020;10(1). https://doi.org/10.1080/20008686.2020.1754538 DOI: https://doi.org/10.1080/20008686.2020.1754538
Hsueh, Huang L, Chen P, Yang CKP. 2004 Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004: 10: 1062–1066.original article https://doi.org/10.1111/j.1469-0691.2004.01009.x DOI: https://doi.org/10.1111/j.1469-0691.2004.01009.x
Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health. 2020; 182:170–2. https://doi.org/10.1016/j.puhe.2020.04.009 DOI: https://doi.org/10.1016/j.puhe.2020.04.009
Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845–8. https://doi.org/10.1038/s41591-020-0897-1 DOI: https://doi.org/10.1038/s41591-020-0897-1
Park R, Cancer C. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. 2020;1(December 2019):2019–21. https://doi.org/10.1056/nejmc2001737 DOI: https://doi.org/10.1056/NEJMc2001737
Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral response to diagnose novel Coronavirus Disease (COVID-19). 2020 Jul 71(15):778-785. https://doi.org/10.1093/cid/ciaa31 DOI: https://doi.org/10.1093/cid/ciaa310
